US HB2374 | 2019-2020 | 116th Congress
Status
Spectrum: Slight Partisan Bill (Democrat 5-3)
Status: Introduced on April 29 2019 - 25% progression, died in chamber
Action: 2020-12-24 - Placed on the Union Calendar, Calendar No. 577.
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on April 29 2019 - 25% progression, died in chamber
Action: 2020-12-24 - Placed on the Union Calendar, Calendar No. 577.
Text: Latest bill text (Introduced) [PDF]
Summary
To enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition and facilitate the efficient review of petitions filed in good faith to raise legitimate public heath concerns, and for other purposes.
Title
Stop STALLING Act Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act
Sponsors
| Rep. Hakeem Jeffries [D-NY] | Rep. James Sensenbrenner [R-WI] | Rep. Jerrold Nadler [D-NY] | Rep. Doug Collins [R-GA] |
| Rep. David Cicilline [D-RI] | Sen. Peter Welch [D-VT] | Rep. Steve Cohen [D-TN] | Rep. Bill Posey [R-FL] |
History
| Date | Chamber | Action |
|---|---|---|
| 2020-12-24 | House | Placed on the Union Calendar, Calendar No. 577. |
| 2020-12-24 | House | Reported by the Committee on Judiciary. H. Rept. 116-694. |
| 2019-04-30 | House | Ordered to be Reported by Voice Vote. |
| 2019-04-30 | House | Committee Consideration and Mark-up Session Held. |
| 2019-04-29 | House | Referred to the House Committee on the Judiciary. |
| 2019-04-29 | House | Introduced in House |
Same As/Similar To
SB1224 (Related) 2019-06-28 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 130.
SB3384 (Related) 2020-03-03 - Read twice and referred to the Committee on Finance.
SB3384 (Related) 2020-03-03 - Read twice and referred to the Committee on Finance.
Subjects
Administrative law and regulatory procedures
Business ethics
Civil actions and liability
Competition and antitrust
Drug safety, medical device, and laboratory regulation
Federal Trade Commission (FTC)
Health
Licensing and registrations
Public participation and lobbying
Business ethics
Civil actions and liability
Competition and antitrust
Drug safety, medical device, and laboratory regulation
Federal Trade Commission (FTC)
Health
Licensing and registrations
Public participation and lobbying
